•  
  •  
  •  
  •  

2025-12-29 21:02:47

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Niraj Cement Structurals Ltd receives order worth Rs. 96.12 crores
  • Cosmo First Appoints Saurabh Jain as CEO of Pet Care Division, Zigly and Head of Corporate Development
  • Nifty Extends Losses for Third Day, Consumer Durables and IT Lead the Decline
  • IDFC FIRST Bank Unveils Gaj: - An Invitation-Only Metal Masterpiece for IDFC Private Banking Customers
  • Lupin signs exclusive licensing agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist

Keywords Selected:  BIOCON

Research

  • Biocon Limited - Generics & research grow; biosimilar stagnates - ICICI Securities
  • Q4FY22 Result Update – Biocon Ltd - ICICI Direct
  • Biocon - Q4FY22 First Cut - ICICI Direct
  • Q3FY22 Result Update - Biocon Ltd - ICICI Direct
  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Biocon Ltd to integrate Biocon Biologics Ltd to create a Unified Global Biopharmaceutical Leader
  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia

Latest Post

  • Niraj Cement Structurals Ltd receives order worth Rs. 96.12 crores
  • Cosmo First Appoints Saurabh Jain as CEO of Pet Care Division, Zigly and Head of Corporate Development
  • Nifty Extends Losses for Third Day, Consumer Durables and IT Lead the Decline
  • IDFC FIRST Bank Unveils Gaj: - An Invitation-Only Metal Masterpiece for IDFC Private Banking Customers
  • Lupin signs exclusive licensing agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024